Ignite Creation Date:
2024-05-05 @ 5:25 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00457340
Status:
COMPLETED
Last Update Posted:
2021-02-18
First Post:
2007-04-04
Brief Title:
Atorvastatin For The Reduction Of Ventricular Arrhythmias
Sponsor:
Pfizers Upjohn has merged with Mylan to form Viatris Inc
Organization:
Pfizer
Study Overview
Official Title:
Cholesterol Lowering and Arrhythmia Recurrences After Internal Defibrillator Implantation CLARIDI
Status:
COMPLETED
Status Verified Date:
2021-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CLARIDI
Brief Summary:
To assess in patients with CAD coronary artery disease and an implantable defibrillator the effect of atorvastatin 80 mg versus placebo on the first recurrence of a ventricular arrhythmia ventricular tachycardia or ventricular fibrillation requiring ICD implantable cardioverter defibrillator intervention within one year after randomization
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None